MRI biomarkers for evaluation of treatment efficacy in preclinical diabetic retinopathy.

Expert opinion on medical diagnostics Pub Date : 2013-07-01 Epub Date: 2013-06-21 DOI:10.1517/17530059.2013.814639
Bruce A Berkowitz, David Bissig, Oliver Dutczak, Shannon Corbett, Rob North, Robin Roberts
{"title":"MRI biomarkers for evaluation of treatment efficacy in preclinical diabetic retinopathy.","authors":"Bruce A Berkowitz,&nbsp;David Bissig,&nbsp;Oliver Dutczak,&nbsp;Shannon Corbett,&nbsp;Rob North,&nbsp;Robin Roberts","doi":"10.1517/17530059.2013.814639","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>One sober consequence of the current epidemic of diabetes mellitus is that an increasing number of people world-wide will partially or completely lose their sight to diabetic retinopathy. Clinically, the sight-threatening complications of diabetes are diagnosed and treated based on visible retinal lesions (e.g., dot-blot hemorrhages or retinal neovascularization). However, such anatomical microvascular lesions are slow to respond with treatment. Thus, there remains an urgent need for imaging biomarkers that are abnormal before retinal lesions are visibly apparent and are responsive to treatment.</p><p><strong>Areas covered: </strong>Here, the development of new MRI methods, such as manganese-enhanced MRI, for evaluating early diabetes-evoked retinal pathophysiology, and its usefulness in guiding new treatments for diabetic retinopathy are reviewed.</p><p><strong>Expert opinion: </strong>In diabetic retinopathy, not all important diagnostic and prognostic needs are well served by optical methods. In the absence of gross anatomy changes, critical times when drug intervention is most likely to be successful at reducing vision loss are missed by most light-based methods and thus provide little help in guiding diagnosis and treatment. For example, before clinical symptoms, is there an optimal time to intervene with drug therapy? Is a drug reaching its target? How does one assess optimal drug dose, schedule, and routes? How well do current experimental models mimic the clinical condition? As discussed herein, MRI is as an analytical tool for addressing these unmet needs. Future clinical applications of MRI can be envisioned such as in clinical trials to assess drug treatment efficacy, or as an adjunct approach to refine or clarify a difficult clinical case. New MRI-generated hypotheses about the pathogenesis of diabetic retinopathy and its treatment are discussed. In the coming years, a substantial growth in the development and application of MRI is expected to address relevant question in both the basic sciences and in the clinic.</p>","PeriodicalId":72996,"journal":{"name":"Expert opinion on medical diagnostics","volume":"7 4","pages":"393-403"},"PeriodicalIF":0.0000,"publicationDate":"2013-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1517/17530059.2013.814639","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on medical diagnostics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1517/17530059.2013.814639","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/6/21 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 17

Abstract

Introduction: One sober consequence of the current epidemic of diabetes mellitus is that an increasing number of people world-wide will partially or completely lose their sight to diabetic retinopathy. Clinically, the sight-threatening complications of diabetes are diagnosed and treated based on visible retinal lesions (e.g., dot-blot hemorrhages or retinal neovascularization). However, such anatomical microvascular lesions are slow to respond with treatment. Thus, there remains an urgent need for imaging biomarkers that are abnormal before retinal lesions are visibly apparent and are responsive to treatment.

Areas covered: Here, the development of new MRI methods, such as manganese-enhanced MRI, for evaluating early diabetes-evoked retinal pathophysiology, and its usefulness in guiding new treatments for diabetic retinopathy are reviewed.

Expert opinion: In diabetic retinopathy, not all important diagnostic and prognostic needs are well served by optical methods. In the absence of gross anatomy changes, critical times when drug intervention is most likely to be successful at reducing vision loss are missed by most light-based methods and thus provide little help in guiding diagnosis and treatment. For example, before clinical symptoms, is there an optimal time to intervene with drug therapy? Is a drug reaching its target? How does one assess optimal drug dose, schedule, and routes? How well do current experimental models mimic the clinical condition? As discussed herein, MRI is as an analytical tool for addressing these unmet needs. Future clinical applications of MRI can be envisioned such as in clinical trials to assess drug treatment efficacy, or as an adjunct approach to refine or clarify a difficult clinical case. New MRI-generated hypotheses about the pathogenesis of diabetic retinopathy and its treatment are discussed. In the coming years, a substantial growth in the development and application of MRI is expected to address relevant question in both the basic sciences and in the clinic.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评价临床前糖尿病视网膜病变治疗效果的MRI生物标志物。
导读:当前糖尿病流行的一个严重后果是,全世界越来越多的人将因糖尿病视网膜病变而部分或完全失明。临床上,糖尿病危及视力的并发症是根据可见的视网膜病变(如斑点出血或视网膜新生血管)进行诊断和治疗的。然而,这种解剖性微血管病变对治疗反应缓慢。因此,迫切需要在视网膜病变明显且对治疗有反应之前发现异常的成像生物标志物。本文综述了新的MRI方法的发展,如锰增强MRI,用于评估早期糖尿病引起的视网膜病理生理,及其在指导糖尿病视网膜病变新治疗中的作用。专家意见:在糖尿病视网膜病变中,并不是所有重要的诊断和预后需要都能通过光学方法得到很好的满足。在没有大体解剖变化的情况下,大多数基于光的方法都错过了药物干预最有可能成功减少视力丧失的关键时刻,因此对指导诊断和治疗帮助不大。例如,在出现临床症状之前,是否存在药物治疗干预的最佳时间?药物是否达到了目标?如何评估最佳药物剂量、方案和途径?目前的实验模型如何很好地模拟临床情况?正如本文所讨论的,MRI是解决这些未满足需求的分析工具。MRI的未来临床应用可以设想,如在临床试验中评估药物治疗效果,或作为一种辅助方法来完善或澄清一个困难的临床病例。本文讨论了关于糖尿病视网膜病变发病机制及其治疗的mri新假设。在未来的几年里,核磁共振成像的发展和应用有望在基础科学和临床中解决相关问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Simtomax, a novel point of care test for coeliac disease. Diagnosis of skeletal muscle channelopathies. Review of latent and lytic phase biomarkers in Kaposi's sarcoma. The precision study: examining the inter- and intra-assay variability of replicate measurements of BGStar, iBGStar and 12 other blood glucose monitors. Novel diagnostic and prognostic biomarkers in esophageal cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1